This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.
In this video, Ronald C. Chen, MD, MPH, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, discusses a prospective, population-based study examining 4-year quality-of-life results among prostate cancer patients who were treated with either active surveillance, radical prostatectomy, or external-beam radiation.
Chen presented results of the study (abstract LBA-11) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.